Comparative Pharmacology
Head-to-head clinical analysis: RIBASPHERE versus VIRA A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIBASPHERE versus VIRA A.
RIBASPHERE vs VIRA-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ribavirin is a nucleoside analog that inhibits viral RNA synthesis by competing with endogenous nucleotides and interfering with viral polymerase activity. It also has immunomodulatory effects.
Vidarabine (VIRA-A) is a purine nucleoside analog that inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination. It also inhibits ribonucleotide reductase, reducing viral DNA synthesis.
800-1200 mg/day orally in 2 divided doses for hepatitis C, in combination with peginterferon alfa or other direct-acting antivirals.
15 mg/kg/day IV infused over 12-24 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life: 40-60 hours in patients with normal renal function; prolonged in renal impairment (up to 100 hours). Accumulation occurs with repeated dosing.
Vidarabine: 0.17-0.25 hours (rapidly deaminated to arabinosylhypoxanthine). Arabinosylhypoxanthine: 3.5-5.5 hours in adults with normal renal function; prolonged to 15-20 hours in severe renal impairment.
Renal (80% unchanged, with remainder as metabolites); biliary/fecal (minor, <10%).
Primarily renal: approximately 40-70% of dose excreted unchanged in urine via glomerular filtration and tubular secretion. A smaller fraction (10-20%) is eliminated as the metabolite hypoxanthine arabinoside. Fecal excretion accounts for <5% of the dose.
Category C
Category C
Antiviral (Nucleoside Analog)
Antiviral (Nucleoside Analog)